Themis Medicare Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, recommended Final Dividend of 0.50 per equity share.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare's board, at its May 20, 2025 meeting, approved audited FY25 results and recommended a final dividend of Rs 0.50 per share (50% on face value of Re 1), aggregating to Rs 4.60 crore, subject to shareholder approval. Standalone total income rose 6.1% YoY to Rs 410.18 crore, but standalone profit for the year dipped 3.3% to Rs 23.92 crore, with Q4 FY25 swinging to a loss of Rs 7.74 crore versus a Rs 3.09 crore profit a year ago. Consolidated profit fell sharply to Rs 29.83 crore from Rs 43.52 crore, dragged by weaker joint venture/associate contribution. The board also approved a management fee MoU with Gedeon Richter (USD 440,000 or 3% of RTML revenue) and re-affirmed the ongoing amalgamation with Gujarat Themis Biosyn Limited at a 118:100 share swap ratio.
The dividend is unchanged from last year, offering modest income but no growth catalyst; weak Q4 and a sharp fall in consolidated profit are likely to weigh on the stock, while the pending GTBL merger remains a key near-term event to watch.